Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889959 | 0.98 | DGKA (0.61) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL149453 | 0.98 | DGKA (0.61) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL1278461 | 0.98 | DGKA (0.61) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL332667 | 0.94 | DGKA (0.50) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL4285868 | 0.94 | DGKA (0.50) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL769549 | 0.92 | DGKA (0.55) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL6061688 | 0.92 | DGKA (0.55) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL50203 | 0.92 | DGKA (0.53) | DGKAMAPTDNM1ALDH1A1L3MBTL1 | |
| SCHEMBL2396997 | 0.92 | DGKA (0.53) | DGKAMAPTDNM1CYP3A4TSHR | |
| SCHEMBL17581556 | 0.92 | DGKA (0.53) | DGKAMAPTDNM1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351566-B1 | PHARMACEUTICAL COMPOSITION IMPROVED IN ABSORPTION THROUGH INTESTINAL TRACT | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20110212140-A1 | PRESSURE-SENSITIVE ADHESIVE COMPOSITION APPLICABLE TO NAIL AND ADHESIVE AGENT FOR NAIL | HANATANI AKINORI | 2011-09-01 | — | — | US | disclosed |
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2351566-A1 | PHARMACEUTICAL COMPOSITION IMPROVED IN ABSORPTION THROUGH INTESTINAL TRACT | Santen Pharmaceutical Co., Ltd (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-1698676-B1 | Pressure-sensitive adhesive composition applicable to nail and adhesive agent for nail | NITTO DENKO CORP (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100178321-A1 | PRESSURE-SENSITIVE ADHESIVE COMPOSITION APPLICABLE TO NAIL AND ADHESIVE AGENT FOR NAIL | HANATANI AKINORI | 2010-07-15 | — | — | US | disclosed |
| US-20090047333-A1 | Pressure-sensitive adhesive composition applicable to nail and adhesive agent for nail | HANATANI AKINORI | 2009-02-19 | — | — | US | disclosed |
| EP-1570839-B1 | COMPOSITION FOR PREPARATION FOR EXTERNAL USE ON SKIN AND METHOD OF USING THE SAME | KOSE CORP (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1698676-A2 | Pressure-sensitive adhesive composition applicable to nail and adhesive agent for nail | NITTO DENKO CORPORATION (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060171908-A1 | Pressure-sensitive adhesive composition applicable to nail and adhesive agent for nail | NITTO DENKO CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060147397-A1 | Composition for preparation for external use on skin and method of using the same | KOSE CORPORATION (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1570839-A1 | COMPOSITION FOR PREPARATION FOR EXTERNAL USE ON SKIN AND METHOD OF USING THE SAME | Kosé Corporation (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-6346537-B1 | ADMINISTERING A MACRO-TRI-HETEROCYCLIC COMPOUND AS ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| US-6316473-B1 | GOOD DRUG RELEASE AND ABSORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6201009-B1 | MIXTURE OF PANTOTHENIC ACID DERIVATIVE, NEUTRALIZED OR ESTERIFIED ACID, AND A NONIONIC SURFACTANT; BIOAVAILABILITY | FUJIREBIO INC. (JP) | 2001-03-13 | — | — | US | disclosed |
| EP-0998927-A1 | Absorption-enhancing composition for pantothenic acid derivative | FUJIREBIO INC. (JP) | 2000-05-10 | — | — | EP | disclosed |
| EP-0978288-A1 | MEDICINAL COMPOSITION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-09 | — | — | EP | disclosed |
| EP-0943327-A1 | MEDICINAL COMPOSITION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SLC10A2, NR1H4, SLC10A6 | DGKA 3424/4885MAPT 4574/4885DNM1 3823/4885 |
| US-20060147397-A1 | Composition for preparation for external use on skin and method of using the same | S100A6, CUTA, CA6 | DGKA 3823/4885MAPT 4470/4885DNM1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.